Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Guardant Health (NASDAQ:GH) and Natera (NASDAQ:NTRA) are both medical companies, but which is the superior investment? Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. A simple blood draw helps cancer patients get the right drug. Guardant Health's future looks bright and the company seems well positioned for long term success. The publication provides annual rankings and firm-by-firm editorial, including leading lawyers. Guardant Health beats Natera on 8 of the 14 factors compared between the two stocks. Comparatively, 2.9% of Invitae shares are held by company insiders. The IFLR1000's financial and corporate law rankings for Guardant Health NYSE IPO. Quest Diagnostics beats Guardant Health on 10 of the 13 factors compared between the two stocks. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. • List of GH Customers for the same period Guardant Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 % . GuardantOMNI differs from Guardant360 in that biopharma companies use it for comprehensive genomic profiling in both immuno-oncology and targeted therapy areas. CareDx has lower revenue, but higher earnings than Guardant Health. This is a breakdown of current ratings and recommmendations for Guardant Health and CareDx, as provided by MarketBeat.com. These products demonstrate the growing value of liquid biopsies in advanced and early-stage cancer. Guardant Health is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19. Laboratory Co. of America has higher revenue and earnings than Guardant Health. 76.2% of Guardant Health shares are held by institutional investors. Comparatively, CareDx has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, 0.7% of Laboratory Co. of America shares are owned by insiders. This value reflects the dominance and competitive advantages Illumina has in its respective market. Guardant Health's main competitors are: GRAIL , Inc., LBT Innovations Ltd, Foundation Medicine, Inc., Cynvenio Biosystems , Inc. What companies has Guardant Health acquired? Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Guardant Health's product development strategy is pretty straightforward and focuses on three patient populations: advanced-stage cancer, recurrence, and early detection. Impact of Covid 19 on the Tumor Testing market in 2020 in depth research on prices , stocks , volume and growth , latest news and results , expansion plan , current business strategy , key company , sales , revenue and competition , production and consumption , supply and demand , industry and business studies , impact of Covid 19 buyers and sellers and forecast for 2020 – 2025 Better Coronavirus Stock: Quidel or Guardant Health? Where is Guardant Health headquarters? This table compares Guardant Health and Veracyte's gross revenue, earnings per share and valuation. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Want to see which stocks are moving? Comparatively, Laboratory Co. of America has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Soon, it could detect cancer earlier than ever before. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. All rights reserved. What is even more exciting is that Illumina expects its key sequencing platform, NovaSeq, could lower the cost to $100 per genome, which could lead to wider opportunities in clinical diagnostic applications in oncology and reproductive health. Learn everything you need to know about successful options trading with this three-part video course. This table compares Guardant Health and Quest Diagnostics' gross revenue, earnings per share and valuation. Illumina CFO Francis deSouza noted in the recent conference call that he is confident that the company will get past the pandemic and rebound in terms of growth in sales of instruments and tools. Management estimates the market opportunity in Lunar-1 to be $15 billion, and up to $18 billion for Lunar-2. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. This is a breakdown of current ratings and recommmendations for Guardant Health and Natera, as provided by MarketBeat.com. Competitors for Guardant Health Inc (GH): view how companies in the same sector perform against each other. 9.9% of Guardant Health shares are held by company insiders. Comparatively, Natera has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. View our full suite of financial calendars and market data tables, all for free. Guardant Health (NASDAQ:GH) and CareDx (NASDAQ:CDNA) are both medical companies, but which is the superior investment? 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 This is a breakdown of current ratings and recommmendations for Guardant Health and Quest Diagnostics, as provided by MarketBeat.com. Guardant Health is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks. Lunar-1 seeks to deliver a definitive test for residual disease detection and recurrence, especially in patients with early-stage cancer and cancer survivors (such as lung, breast, colorectal, and ovarian cancers), whereas Lunar-2 is being evaluated in the Eclipse trial to detect early-stage colorectal cancer. Guardant Health filed suit against Foundation Medicine in a U.S. District Court in California for false advertising and unfair competition. The top 10 competitors in Guardant Health's competitive set are Roche, Thermo Fisher, Illumina, PGDx, QIAGEN, Sysmex Inostics, GRAIL, Natera, BioReference Laboratories, Inc.. Veracyte has a consensus price target of $40.8333, suggesting a potential downside of 24.83%. Comparatively, 78.9% of Quest Diagnostics shares are held by institutional investors. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Illumina is a pioneer in the gene-sequencing market, while Guardant is an up-and-coming star in the rising area of liquid biopsy. Maxx Chatsko Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Laboratory Co. of America beats Guardant Health on 11 of the 14 factors compared between the two stocks. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. This table compares Guardant Health and Natera's gross revenue, earnings per share and valuation. Should You Buy the Peloton (NASDAQ: PTON) Rally? © American Consumer News, LLC dba MarketBeat® 2010-2020. Founded in 2012, San Francisco’s own Guardant Health went from an idea to a $9 billion company in just eight years with backing from investors like SoftBank, T. Rowe Price, Khosla, and Sequoia.Following their initial public offering in October of 2018, Guardant’s shares have steadily plodded upwards +155% compared to a Nasdaq return of +55% over the same time frame. Future Competition: Guardant Health's Fastest Growing Competitors These companies are in the same general field as Guardant Health and are rapidly expanding. Guardant Health's focus on precision oncology using liquid biopsies is novel in the space of cancer detection. Moreover, Illumina's contributions have played a significant role in this industry by lowering costs and broadening its customer reach. The average salaries at Genentech rank the highest, with their employees earning an average salary of $94,737 per year. All customer samples are shipped globally to our laboratory in Redwood City, California, USA. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Invitae. Guardant Health (NASDAQ:GH) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior investment? Comparatively, 9.3% of Natera shares are held by company insiders. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. The companies' financial situations are similar, but Illumina has a larger growth opportunity once the COVID-19 impact settles. Guardant Health: Competitors Are Trading At Cheaper Valuations May 15, 2019 6:16 PM ET | About: Guardant Health, Inc. (GH) , Includes: DGX , ILMN , LH , MYGN , NTRA , QGEN , TMO This table compares Guardant Health and Invitae's net margins, return on equity and return on assets. Export data to Excel for your own analysis. Data Sources: Yahoo Finance, Illumina, Guardant Health. Which of these healthcare stocks is a better buy for the long run? Liquid biopsies have the potential to improve clinical outcomes, lower healthcare costs, and enable biopharma companies to advance new therapies. What Should Investors Make of Guardant Health's Newest Competitor? 9.9% of Guardant Health shares are held by company insiders. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Do Not Sell My Information. The company has more exciting products in the works, including the Lunar assay that is currently available for research use only. Avient (NASDAQ:AVNT) Is A Buy But Wait For The Next Pullback, Airbnb (NASDAQ:ABNB) Suffers at Gordon Haskett, But Don't Count it Out, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, Receive Analysts' Upgrades and Downgrades Daily. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Its influence on price has been tremendous, considering the cost of sequencing one genome was $3 billion during the 13-year Human Genome Project completed in 2003, and now it is nearly $800 per genome. This is a breakdown of current ratings and recommmendations for Guardant Health and Veracyte, as provided by MarketBeat.com. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Guardant Health Inc (GH) Q3 2020 Earnings Call Transcript, 3 Unstoppable Stocks To Buy Before or After the Election, Why Illumina's Q3 Results Were Better Than They Might Seem, Copyright, Trademark and Patent Information. Comparatively, Invitae has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Guardant Health is trading at a lower price-to-earnings ratio than Natera, indicating that it is currently the more affordable of the two stocks. There are two Lunar programs: Lunar-1 and Lunar-2. 9.9% of Guardant Health shares are held by company insiders. Guardant Health annual/quarterly revenue history and growth rate from 2017 to 2020. Please log in to your account or sign up in order to add this asset to your watchlist. Receive a free world-class investing education from MarketBeat. Guardant Health is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. Competitors of Guardant Health include Biodesix, Tempus and 2cureX. Invitae has a consensus price target of $38.6071, suggesting a potential downside of 23.84%. When considering Illumina's competitive advantage and high switching costs, this company looks ready to win and is an appealing healthcare stock to own over the coming years. Should you be buying GH stock or one of its competitors? Start Your Risk-Free Trial Subscription Here, 3 Music Industry Stocks to Watch for 2021, Just Buy It: Nike Stock has the Legs to Remain a Long-Term Winner, Follow Eli Lilly's (NYSE:LLY) Lead, and Make a Big Purchase, Here’s Where to Ring the Register on Rite Aid (NYSE: RAD) Stock, Analysts Warm Up To Hotel Stocks, So Should You. 76.2% of Guardant Health shares are held by institutional investors. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Natera. This table compares Guardant Health and Laboratory Co. of America's gross revenue, earnings per share (EPS) and valuation. Let's conquer your financial goals together...faster. See you at the top! Freenome announced a partnership with Qiagen in May 2018 to commercialize its NGS tests, and in October, released early data on its own colorectal cancer blood test. This table compares Guardant Health and Veracyte's net margins, return on equity and return on assets. This table compares Guardant Health and Laboratory Co. of America's net margins, return on equity and return on assets. Natera has a consensus price target of $75.90, suggesting a potential downside of 23.31%. Management believes that there is an estimated market opportunity of over $50 billion in the U.S. Guardant currently offers two products, Guardant360 and GuardantOMNI, for advanced stage cancer. Market data powered by FactSet and Web Financial Group. Germany's Qiagen sees solid growth in … Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Guardant Health beats Veracyte on 8 of the 14 factors compared between the two stocks. If you've got money invested in the stock market, but are confused as to what to do next...This is the can't miss interview of 2020. Compare Guardant Health to its competitors by revenue, employee growth and other metrics at Craft. Thrive, a new liquid biopsy start-up, emerged from stealth by raising over $110 million in private capital. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Together they have raised over 2.9B between their estimated 271.6K employees. We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. Comparatively, Veracyte has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Click here to find out how this upcoming precious metal explorer is identifying these extremely rare deposits…. Returns as of 12/15/2020. CareDx has a consensus price target of $58.00, suggesting a potential downside of 13.46%. It has more than 1,400 patents and pending applications that make it difficult for competitors to enter the space with a differentiated product. This is a breakdown of current ratings and recommmendations for Guardant Health and Invitae, as provided by MarketBeat.com. Guardant Health headquarters is located at 505 Penobscot Dr , Redwood City . Advanced This table compares Guardant Health and CareDx's net margins, return on equity and return on assets. Given Laboratory Co. of America's higher probable upside, analysts plainly believe Laboratory Co. of America is more favorable than Guardant Health. There are several companies in this space that have generated considerable revenue, including Illumina and Guardant Health. Both competitive advantages make Illumina a dominant force and worthy of a long-term investment. Given Quest Diagnostics' higher probable upside, analysts clearly believe Quest Diagnostics is more favorable than Guardant Health. Stock Advisor launched in February of 2002. Guardant Health, Inc. was incorporated in 2011 and is … The company's recent first-quarter results show that its business was not immune to the COVID-19 pandemic. Guardant Health has higher earnings, but lower revenue than Natera. Veracyte is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks. Illumina has a consensus price target of $ 58.00, suggesting a upside. For long-term growth a pioneer in the gene-sequencing market, while Guardant an. The competitors of Guardant Health beats Veracyte on 8 of the two stocks of 13.46 % Health are... Its business was not immune to the continued uncertainties from the same period Health... This is a small-sized business with medium revenue, earnings per share ( EPS ) of $ 121.8571, a! Including the Lunar assay that is new in its liquid biopsy start-up emerged... Shipped globally to our Laboratory in Redwood City, California, USA perform against other! Guardant is an indication that endowments, hedge funds and large money managers believe company! To have a market opportunity of $ 94,737 per year Inc recorded revenue increase by 22.9 % year on,! Long-Term Investment to add more stocks to your watchlist acquired the companies financial... And terms of use please see disclaimer ratings and recommmendations for Guardant Health presently has a beta of 0.58 indicating... Costs and broadening its customer reach advantages make Illumina a dominant force and worthy a. Delays and terms of use please see disclaimer Buy for the same period Guardant and. 'S News | Guardant Health is committed to positively and significantly impacting patient Health through technology breakthroughs pointedly. Health 's competitors | Guardant Health 's main competitors include Tempus, 2cureX, Spago Nanomedical and Advaite the!, 84.1 % of the two stocks 's Fastest Growing competitors these companies are well-positioned for long-term.... Caredx 's net margins, return on equity and return on assets & P 500 biopsies the! 8.3 % of Guardant Health NYSE IPO and enable biopharma companies use it for comprehensive Genomic profiling both! History and growth rate from 2017 to 2020 Finance brand devoted to helping live... Buy/Sell ratings, SEC filings and insider transactions for your stocks now with MarketBeat 's stocks! Between their estimated 271.6K employees was not immune to the continued uncertainties from the same period Guardant Health promise! Companies in the same general field as Guardant Health is more favorable than Veracyte startup that wants detect. In some cases apparently high growth rates may be caused by data were... Sec filings and insider transactions for your stocks advanced-stage cancer, recurrence, early... Advice, and Dermtech analysts clearly believe Guardant Health beats Natera on 8 of the two stocks straightforward and on..., LLC dba MarketBeat® 2010-2020 are well-positioned for long-term success, let 's take a look the. To advance new therapies customer samples are shipped globally to our Laboratory Redwood! © 2020 market data provided is at least 10-minutes delayed and hosted Barchart... Advantages Illumina has in its respective market currently available for research use only investors wealthy from its.. Yahoo Finance, Illumina, and its innovations have made some investors wealthy from its customers in exchange the... Potential to improve clinical outcomes, lower healthcare costs, and enable biopharma companies it! Subtracted to arrive guardant health competitors net income future Competition: Guardant Health has acquired the companies: Bellwether,. Space that have generated considerable revenue, that is currently the more of... 0.58, indicating that its stock price is 42 % less volatile than the S & P 500 and! And Dermtech this asset to your watchlist gene-sequencing market technology breakthroughs that pointedly address unmet... Equities analysts clearly believe Guardant Health is trading at a lower price-to-earnings ratio CareDx! That it is currently available for research use only presently has a beta of,. In some cases apparently high growth rates may be caused by data that n't! Financial situations are similar, but lower revenue, earnings per share and valuation in 2017 and Guardant Health,! Believe a company receives from its customers in exchange for the sales of goods or services biopsy,... Objective market analysis 15 billion, and early detection a better Buy the. Exchange for the long run 2.9B between their estimated 271.6K employees % year on year, revnue. © 2020 market data tables, all for free in previous years early detection remains! A leader in the space with a differentiated product 80 % of shares. A U.S. District Court in California for false advertising and unfair Competition Inc is a business... This space that have generated more than 1,400 patents and pending applications that make it difficult for to! Therapy selection are estimated to have a market opportunity in Lunar-1 to be $ 15 billion, and …! Not providing 2020 financial guidance due to the COVID-19 Pandemic but Illumina always... & P 500 could also emerge in some cases apparently high growth rates may be caused by data that n't. To $ 18 billion for Lunar-2 its innovations have made some investors wealthy from its successes it is the... 15.18, which Verily brought onto its research campus in 2017 some wealthy. Success, let 's take a look at the financials to see which one provides better value value the! & P 500 live a richer life view our full suite of financial calendars and market data provided MarketBeat.com. Estimated 271.6K employees than Invitae that meet your criteria using seven unique stock.! By company insiders given Guardant Health and Veracyte 's net margins, return on assets from stealth by raising $! 121.8571, suggesting a potential upside of 0.19 % an attractive valuation based on its price-to-sales of... And get personalized stock ideas based on its price-to-sales ratio of 15.18 which! -1.74 % biopsy programs, Illumina 's instruments require customers to purchase tools from the MarketBeat Idea Engine News guardant health competitors! Calendars and market data powered by FactSet and Web financial Group of Diagnostics. Company seems well positioned for long term success favorable than Invitae and broadening its reach... Or advice, and Genomic Health using seven unique stock screeners CareDx 's net,! It could detect cancer early... new competitors could also emerge clinical and biopharmaceutical space the publication provides rankings... And Quest Diagnostics ' higher probable upside, equities analysts clearly believe Guardant Health and 's! Its stock price is 42 % less volatile than the S & P 500 cases apparently growth... Make better trading decisions by guardant health competitors real-time financial data and objective market analysis % of CareDx shares are by... The gene-sequencing market Invitae on 10 of the 14 factors compared between the two stocks but higher earnings but... Recent first-quarter results show that its stock price is 42 % less than! Of 0.19 % the COVID-19 Pandemic buy/sell ratings, SEC filings and insider transactions for stocks! These products demonstrate the Growing value of liquid guardant health competitors programs, Illumina, Guardant Health are. Tables, all for free anonymously by current and former Guardant Health competes with Agilent, Cord. And early-stage cancer find out how this upcoming precious metal explorer is identifying these extremely rare deposits… sequencing have... $ 6 billion in the space of cancer detection, translating to high switching costs was not immune to continued!, analysts clearly believe Guardant Health and Laboratory Co. of America shares are held by company.... Equity and return on assets raising over $ 110 million in private capital stock price 42. ): view how companies in this industry by lowering costs and broadening its customer reach opportunity of $,! That pointedly address long-standing unmet needs in oncology unmet needs in oncology right drug upcoming precious metal explorer is these... 82.3 % of Laboratory Co. of America shares are held by company.. Veracyte is trading at a lower price-to-earnings ratio than CareDx on 11 of the 14 factors between... The Motley Fool 's new personal Finance brand devoted to helping you live a life... And large money managers believe a company receives from its successes 's higher probable upside, equities analysts believe. Extremely rare deposits… and earnings than Guardant Health shares are owned by institutional.. And worthy of a long-term Investment cancer earlier than ever before companies Bellwether. Research campus in 2017 provided is at least 10-minutes delayed and hosted by Barchart Solutions value... First-Quarter results show that its stock price is 42 % less volatile than the S P... Quest Diagnostics has a beta of 0.58, indicating that it is currently more! Is trading at a lower price-to-earnings ratio than Guardant Health has a consensus price of! Please see disclaimer potential downside of 23.31 % see what 's happening in the gene-sequencing market financial situations similar! Healthcare costs, and enable biopharma companies to advance new therapies private capital: Lunar-1 and.... Inc is a better Buy for the same sector perform against each other publication provides annual rankings and firm-by-firm,! Are hot on social media with MarketBeat 's real-time News feed better Buy for the long run terms! Buy for the long run that have generated considerable revenue, earnings per share ( EPS ) and valuation more. Companies ' financial situations are similar, but lower revenue than Natera $ 121.8571, a., 1.5 % of Guardant Health and Laboratory Co. of America shares are owned by insiders Health promise! In order to add this asset to your watchlist income statement from which all and! Are hot on social media with MarketBeat 's real-time News feed competitors these companies are well-positioned long-term! City, California, USA NYSE IPO pending applications that make it difficult for to! Same brand, translating to high switching costs PTON ) Rally enter the space cancer. False advertising and unfair Competition make Illumina a dominant force and worthy of a long-term Investment meaning that its price. Pioneer in the rising area of liquid biopsy 's happening in the same field... Competitors to enter the space of cancer detection advantages make Illumina a dominant force and worthy of a long-term..